Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
71 - 80of about 316 News
71 - 80of about 316 News
August 05, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
READ MORE
August 03, 2021
Not intended for U.S. and UK Media
Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile
READ MORE
July 29, 2021
Bayer Provides Update on Path to Closure of Roundup™ Litigation
READ MORE
July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
READ MORE
July 09, 2021
Not intended for U.S. and UK Media
U.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetes
READ MORE
June 23, 2021
Not intended for U.S. and UK Media
Vericiguat approved in Japan to treat patients with chronic heart failure
READ MORE
June 21, 2021
Not intended for U.S. and UK Media
Bayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU
READ MORE
June 08, 2021
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease
READ MORE
June 03, 2021
Not intended for U.S. and UK Media
Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
READ MORE
May 26, 2021
Bayer announces five-point plan to effectively address potential future Roundup™ claims
READ MORE
71 - 80of about 316 News
71 - 80of about 316 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more